Search Results
You are looking at 1 - 8 of 8 items for
- Author: J. S. Williams x
- Refine by access: All content x
Search for other papers by A. R. Menino Jr in
Google Scholar
PubMed
Search for other papers by J. S. Williams in
Google Scholar
PubMed
Effects of the metabolic inhibitors cycloheximide and ouabain on development in vitro and plasminogen activator production by sheep embryos were investigated. Embryos (n = 152) from the eight-cell to the morula stage were surgically collected from naturally mated, oestrus-synchronized and superovulated Polypay ewes. In Expt 1, embryos (n = 104) were grouped by cell stage, cultured in Whitten's medium with 1.5% BSA containing 0, 0.1 or 1.0 μg cycloheximide ml−1 for 24 h, washed and cultured in this medium for 168 h. In Expt 2, morulae (n = 48) were cultured for 48 h in Whitten's medium with 1.5% BSA transferred to the same medium containing 0 or 1.0 mmol ouabain l−1 and cultured for 24 h, and then washed and cultured in this medium for 120 h. At 24 h intervals in both experiments, the medium was recovered and analysed for plasminogen activator. In Expt 1, eight-cell embryos underwent limited development; little difference in the production of plasminogen activator due to cycloheximide treatment was therefore observed. Compared with medium without cycloheximide, treatment with 1.0 μg cycloheximide ml−1 reduced the number of 16-cell embryos (P < 0.05) and morulae (P < 0.05) (60% versus 10% and 77% versus 8%, respectively) that began to hatch. The mean production of plasminogen activator was greatest in embryos cultured initially as morulae compared with that of 16-cell and eight-cell embryos (P < 0.05). Cycloheximide treatment suppressed the mean production of plasminogen activator in a dose-dependent manner (P < 0.05). In Expt 2, fewer embryos (P < 0.05) developed to the blastocyst and expanded blastocyst stages following ouabain treatment (83% and 4%, respectively) compared with embryos not exposed to ouabain (100% and 100%, respectively). Embryos treated with ouabain produced less plasminogen activator than did untreated embryos (P < 0.05). These results suggest that developmental changes caused by treating sheep embryos with cycloheximide or ouabain are reflected by changes in the production of plasminogen activator.
Search for other papers by H O Goyal in
Google Scholar
PubMed
Search for other papers by T D Braden in
Google Scholar
PubMed
Search for other papers by C S Williams in
Google Scholar
PubMed
Search for other papers by J W Williams in
Google Scholar
PubMed
In this review, we report permanent dysmorphogenesis of the penis and loss of fertility in adult rats treated neonatally with estrogen. Specifically, we report replacement of smooth muscle cells and cavernous spaces by fat cells in the corpus cavernosum penis, but not in the adjoining corpus spongiosum. Induction of these novel, region-specific phenotypes is dose-dependent, requires a critical window of exposure and associated with decreased testosterone and up-regulation of estrogen receptor α (ERα). The resistance of ERα knockout mice to develop these abnormalities implies an unequivocal role for ERα in mediating maldevelopment of the penis. Additionally, the prevention of estrogen-inducible penile abnormalities by ER antagonist ICI 182 780 implies that a functional ER-mediated pathway is essential for inducing penile abnormalities. Likewise, the ability of testosterone or dihydrotestosterone to negate these abnormalities suggests a role for an androgen receptor (AR)-mediated pathway. Taken together, these observations led us to hypothesize that neonatal estrogen exposure, via an ER-mediated pathway (direct action) or an AR-mediated pathway (indirect action through decreased testosterone) or both pathways, up-regulates ERα expression in stromal cells of the penis, which are then reprogrammed such that their differentiation into smooth muscle cells is inhibited and their differentiation into adipocytes is stimulated.
Search for other papers by Lisa M. Williams in
Google Scholar
PubMed
Search for other papers by M. Hollingsworth in
Google Scholar
PubMed
Search for other papers by J. S. Dixon in
Google Scholar
PubMed
Summary. The isolated cervix from non-pregnant, early Day 22 pregnant (late pregnant) and parturient rats was studied. Cyclic loading and unloading tensile tests showed that the creep properties of the cervix were greater in late pregnant than in non-pregnant rats. This change in tensile properties, or softening, was associated with a marked rise in % of water and a fall of collagen concentration (as % of wet but not dry weight). These findings, plus electron micrographs showing a marked increase in extracellular matrix, separation of bundles of collagen fibrils and active fibroblasts, suggest that softening is related to controlled tissue hydration. Cervices were also removed from 3 groups of rats killed at different times during the 3-h parturient period and creep rate measured by continuous loading. A nearly 3-fold increase in creep rate over this period indicates that there is a second stage of cervical softening in pregnancy which precedes dilatation at parturition.
Search for other papers by B G White in
Google Scholar
PubMed
Search for other papers by S J Williams in
Google Scholar
PubMed
Search for other papers by K Highmore in
Google Scholar
PubMed
Search for other papers by D J MacPhee in
Google Scholar
PubMed
The underlying mechanisms that regulate uterine contractions during labour are still poorly understood. A candidate regulatory protein is heat shock protein 27 (Hsp27). It belongs to the small heat shock protein family and can regulate actin cytoskeleton dynamics, act as a chaperone, and may regulate contractile protein activation. As a result, we hypothesized that Hsp27 expression would be highly induced during late pregnancy and labour. Hsp27 mRNA expression was significantly elevated (P < 0.05) on days 17 to 22 of gestation. In addition, immunoblot analysis demonstrated that detection of total Hsp27 increased (P < 0.05) between day 21 and 1 day post-partum (PP) inclusive. Since phosphorylation of Hsp27 has been reported to be a prerequisite for smooth muscle contraction, we examined the temporal and spatial expression of Ser-15 phosphorylated Hsp27. Immunoblot analysis showed that the detection of Ser-15 phosphorylated Hsp27 significantly increased (P < 0.05) between days 19 and 23 (active labour) inclusive, in parallel with detection of total Hsp27. Immunocytochemical analysis of Ser-15 phosphorylated Hsp27 expression in situ demonstrated that phosphorylated Hsp27 in circular muscle became detectable in peri-nuclear and membrane regions on days 19 to 22, but was primarily restricted to the cytoplasm on days 23 to PP. In contrast, phosphorylated Hsp27 in longitudinal muscle was primarily detected in myocyte membranes on days 15 to 22, and then also became detectable in the cytoplasm of myocytes on days 23 and PP. Our results demonstrate that Hsp27 expression is highly upregulated during late pregnancy and labour and suggest that Hsp27 is a potential candidate contraction-associated protein.
Search for other papers by H O Goyal in
Google Scholar
PubMed
Search for other papers by T D Braden in
Google Scholar
PubMed
Search for other papers by P S Cooke in
Google Scholar
PubMed
Search for other papers by M A Szewczykowski in
Google Scholar
PubMed
Search for other papers by C S Williams in
Google Scholar
PubMed
Search for other papers by P Dalvi in
Google Scholar
PubMed
Search for other papers by J W Williams in
Google Scholar
PubMed
Previously, we reported an association between estrogen receptor-α (ERα) upregulation and detrimental effects of neonatal diethylstilbestrol (DES) exposure in the rat penis. The objective of this study was to employ the ERα knockout (ERαKO) mouse model to test the hypothesis that ERα mediates DES effects in the developing penis. ERαKO and wild-type C57BL/6 mice received oil or DES at a dose of 0.2 μg/pup per day (0.1 mg/kg) on alternate days from postnatal days 2 to 12. Fertility was tested at 80–240 days of age and tissues were examined at 96–255 days of age. DES caused malformation of the os penis, significant reductions in penile length, diameter, and weight, accumulation of fat cells in the corpora cavernosa penis, and significant reductions in weight of the bulbospongiosus and levator ani muscles in wild-type mice. Conversely, ERαKO mice treated with DES developed none of the above abnormalities. While nine out of ten male mice sired pups in the wild-type/control group, none did in the wild-type/DES group. ERαKO mice, despite normal penile development, are inherently infertile. Both plasma and intratesticular testosterone levels were unaltered in the DES-treated wild-type or DES-treated ERαKO mice when compared with controls, although testosterone concentration was much higher in the ERαKO mice. Hence, the resistance of ERαKO mice to developing penile abnormalities provides unequivocal evidence of an obligatory role for ERα in mediating the harmful effects of neonatal DES exposure in the developing penis.
Search for other papers by A. R. Scanlon in
Google Scholar
PubMed
Search for other papers by S. J. Sunderland in
Google Scholar
PubMed
Search for other papers by T. L. Martin in
Google Scholar
PubMed
Search for other papers by D. Goulding in
Google Scholar
PubMed
Search for other papers by D. O'Callaghan in
Google Scholar
PubMed
Search for other papers by D. H. Williams in
Google Scholar
PubMed
Search for other papers by D. R. Headon in
Google Scholar
PubMed
Search for other papers by M. P. Boland in
Google Scholar
PubMed
Search for other papers by J. J. Ireland in
Google Scholar
PubMed
Search for other papers by J. F. Roche in
Google Scholar
PubMed
Two experiments were conducted in cyclic beef heifers to determine whether active immunization against bovine inhibin α 1–26 Gly-Tyr (bINH) affected follicular dynamics, hormone concentration or ovulation rate. In Expt 1, heifers (n = 9) were actively immunized against bINH conjugated to human α globulins (HAG) using bisdiazotized benzidine in non-ulcerative Freund's adjuvant (NUFA; primary on day 0; booster injections on days 53, 84 and 116 using conjugated bINH and on days 176 and 366 using unconjugated bINH; ten heifers were used as controls). Ovaries were examined daily using ultrasound scanning (days 70–155 and 384–391) and corresponding blood samples were collected for bINH antibody titre, luteinizing hormone (LH), follicle-stimulating hormone (FSH) and oestradiol determinations. Four treated and four control heifers were injected with 10 μg gonadotrophin-releasing hormone (GnRH) on day 386 (day 2 of the oestrous cycle). Although bINH-immunized heifers had variable antibody titres ranging from 4 to 50% I125-labelled bINH bound to serum diluted 1:2000, ovulation rate was unaffected. In oestrous cycles with three dominant follicles, the ovulatory follicles grew faster (2.5 ± 0.2 versus 1.6 ± 0.3 mm day−1; mean ± sem), had shorter durations of growth (5.7 ± 0.8 versus 9.6 ± 1.6 days) and duration of detection (7.5 ± 0.8 versus 12.0 ± 2.4 days) in immunized heifers. Mean concentrations of FSH, LH and oestradiol were unaltered in most cases during oestrous cycles in bINH-immunized compared with control heifers. There was no significant difference in the percentage increase in FSH or LH, after GnRH injection, between control and immunized heifers. As ovulation rate was unaltered in the first experiment, a second similar study was designed using a different immunization protocol. In Expt 2, heifers were immunized with bINH conjugated to human serum albumin using glutaraldehyde with the following doses: 0.0 (control; n = 7), 0.33 (n = 7), 1.0 (n = 8) and 3.0 (n = 7) mg. Three booster immunizations were given 33, 66 and 209 days after primary immunization. Immunization increased the number of oestrous cycles with multiple ovulations (42 of 132 (32%) oestrous cycles examined) compared with controls (1 of 30 (3.3%) oestrous cycles examined). Neither titre nor ovulation rate was affected by dose of bINH used. In summary, following bINH immunization, ovulation rate was not increased despite changes in follicular dynamics in Expt 1, but was increased in 32% of oestrous cycles in Expt 2. We conclude that immunization protocols can affect responsiveness of heifers to bINH immunization, and that immunization against inhibin can increase ovulation rate.
Search for other papers by J S Redmond in
Google Scholar
PubMed
Department of Animal Science, Federal University of Viçosa, Texas AgriLife Research, Physiologie de la Reproduction et des Comportements, Texas A&M University, College Station, Texas 77843, USA
Search for other papers by G G Macedo in
Google Scholar
PubMed
Department of Animal Science, Federal University of Viçosa, Texas AgriLife Research, Physiologie de la Reproduction et des Comportements, Texas A&M University, College Station, Texas 77843, USA
Search for other papers by I C Velez in
Google Scholar
PubMed
Search for other papers by A Caraty in
Google Scholar
PubMed
Department of Animal Science, Federal University of Viçosa, Texas AgriLife Research, Physiologie de la Reproduction et des Comportements, Texas A&M University, College Station, Texas 77843, USA
Search for other papers by G L Williams in
Google Scholar
PubMed
Search for other papers by M Amstalden in
Google Scholar
PubMed
The onset of puberty in mammals involves an increase in the pulsatile release of GNRH and LH. The KISS1 gene is essential for pubertal development, and its product, kisspeptin, stimulates the release of LH. The objective of this study was to determine the effects of kisspeptin in the hypothalamic–adenohypophyseal–gonadal axis of prepubertal ewe lambs. Ewe lambs (28 weeks of age) were treated intravenously with saline (control, n=6) or kisspeptin (20 μg kisspeptin; n=6) every hour for 24 h. Kisspeptin stimulated pulse-like release of LH within 15 min following injections, and increased the frequency and amplitude of LH pulses, and mean circulating concentrations of LH and estradiol. A surge-like release of LH was observed in four kisspeptin-treated lambs beginning 17 h after the onset of treatment, and all four lambs had elevated circulating concentrations of progesterone within 5 days post-treatment. However, circulating concentrations of progesterone decreased within 2 days after the initial rise in three of the four ewe lambs, indicating that induced luteal activity was of short duration. The proportion of lambs that were pubertal (defined by circulating concentrations of progesterone above 1 ng/ml for at least 7 days) by 35 weeks of age (8/11) and the mean age at puberty (32±1 weeks) for those reaching puberty within the experimental period did not differ between treatments. Results support a role for kisspeptin in the activation of the hypothalamic–adenohypophyseal axis leading to the onset of puberty in ewe lambs.
Search for other papers by Macarena B Gonzalez in
Google Scholar
PubMed
Search for other papers by Carl A Campugan in
Google Scholar
PubMed
Search for other papers by Haley S Connaughton in
Google Scholar
PubMed
Search for other papers by Eryk Andreas in
Google Scholar
PubMed
Search for other papers by Yasmyn E Winstanley in
Google Scholar
PubMed
Search for other papers by Elisha J Williams in
Google Scholar
PubMed
Search for other papers by Camilla L Dorian in
Google Scholar
PubMed
Search for other papers by Sarah A Robertson in
Google Scholar
PubMed
Search for other papers by Cheryl Shoubridge in
Google Scholar
PubMed
Search for other papers by Rebecca L Robker in
Google Scholar
PubMed
In Brief
Aging in men is associated with diminished sperm quality and a higher incidence of altered fetal development and miscarriage in resultant pregnancies. This study in mice identifies a therapeutic compound that, when administered to aged males, improves sperm quality, subsequent embryo development and post-natal offspring health.
Abstract
Aging in men is associated with diminished sperm quality and a higher incidence of altered fetal development and miscarriage in resultant pregnancies. We used a mouse model of advanced paternal age to characterize embryonic development in older male mice and tested whether pre-conception treatment with the mitochondrial activator BGP-15 improves reproductive outcomes in old males. Like older men, reproductively old male mice had higher levels of sperm DNA damage and delayed pre-implantation development, associated with a reduced fetal weight and placental weight. Analysis of neonatal outcomes of in vivo-conceived offspring found that pups sired by old males were smaller, had delayed locomotor development, and increased mortality. BGP-15 treatment for 5 days prior to conception reduced sperm DNA oxidation levels and improved on-time embryo development after IVF and pup survival. BGP-15 treatment for 3 weeks prior to conception improved on-time pre-implantation embryo development and fetal viability and increased fetal size in pregnancies sired by old males. These results validate that ageing negatively affects male fertility and offspring physiology and indicates that pre-conception treatment with BGP-15 has the potential to improve sperm quality as well as early embryo development and post-natal health.
